Registered Number: 06946223
England & Northern Ireland

ASSET PHARMA RESOURCES LIMITED

Unaudited Financial Statements

Period of accounts

Start date: 01 July 2022

End date: 30 June 2023

ASSET PHARMA RESOURCES LIMITED
Contents Page
For the year ended 30 June 2023

ASSET PHARMA RESOURCES LIMITED
Company Information
For the year ended 30 June 2023

Director	Christopher Bouffard
Registered Number	06946223
Registered Office	Kao Hockham Building Edinburgh Way Harlow ESSEX CM20 2NQ
Accountants	M & A ACCOUNTANCY SERVICES S.L Calle Los Huertos 97, LN5 Nerja Malaga Spain 29780

ASSET PHARMA RESOURCES LIMITED
Director's Report
For the year ended 30 June 2023

Director's report and financial statements

The director presents his/her/their annual report and the financial statements for the year ended 30 June 2023.

Principal activities

Principal activity of the company during the financial year was of ...

Director

The director who served the company throughout the year was as follows:

Christopher Bouffard

Statement of director's responsibilities

The director is responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations and in accordance with United Kingdom Generally Accepted Accounting Practice.
Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (Financial Reporting Standard 102). Under company law the director must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the profit or loss of the company for that period.
In preparing these financial statements, the director is required to :

- select suitable accounting policies and then apply them consistently
- make judgements and accounting estimates that are reasonable and prudent
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. The director is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The director is responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom, governing the preparation and dissemination of financial statements, may differ from legislation in other jurisdictions

On behalf of the board.

Christopher Bouffard
Director

Date approved: 04 March 2024

ASSET PHARMA RESOURCES LIMITED
Accountants' Report
For the year ended 30 June 2023

Report to the directors on the preparation of the unaudited statutory accounts of ASSET PHARMA RESOURCES LIMITED for the year ended 30 June 2023
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of ASSET PHARMA RESOURCES LIMITED for the year ended 30 June 2023 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given to us.

As a practising member firm of the Institute of Financial Accountants (IFA), we are subject to its ethical and other professional requirements which are detailed at https://www.ifa.org.uk/about-us/acting-in-the-public-interest/memberregulations.

This report is made solely to the Board of Directors of ASSET PHARMA RESOURCES LIMITED, as a body, in accordance with the terms of our engagement letter dated 04 March 2024 . Our work has been undertaken solely to prepare for your approval the accounts of ASSET PHARMA RESOURCES LIMITED and state those matters that we have agreed to state to the Board of Directors of ASSET PHARMA RESOURCES LIMITED, as a body, in this report.To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than ASSET PHARMA RESOURCES LIMITED and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that ASSET PHARMA RESOURCES LIMITED has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit or loss of ASSET PHARMA RESOURCES LIMITED.You consider that ASSET PHARMA RESOURCES LIMITED is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit of the accounts of ASSET PHARMA RESOURCES LIMITED. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements 30 June 2023.

....

M & A ACCOUNTANCY SERVICES S.L
Calle Los Huertos 97, LN5
Nerja
Malaga
Spain
29780
04 March 2024

ASSET PHARMA RESOURCES LIMITED
Statement of Financial Position
As at 30 June 2023

	Notes	2023	2022
		£	£
Current assets			
Debtors	4	18,779	11,341
Cash at bank and in hand		190	18,604
		18,969	**29,945**
Creditors: amount falling due within one year	5	(903)	(4,846)
Net current assets		**18,066**	**25,099**
Total assets less current liabilities		18,066	25,099
Creditors: amount falling due after more than one year	6	(19,515)	(25,000)
Net liabilities		**(1,449)**	**99**
Capital and reserves			
Called up share capital		1,000	1,000
Profit and loss account		(2,449)	(901)
Shareholder's funds		**(1,449)**	**99**

For the year ended 30 June 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The financial statements were approved by the director on 04 March 2024 and were signed by:

Christopher Bouffard
Director

ASSET PHARMA RESOURCES LIMITED
Statement of Changes in Equity
For the year ended 30 June 2023

	Equity share capital	Retained Earnings	Total
	£	£	£
At 01 July 2021	**1,000**	**(713)**	**287**
Profit for the year		16,812	16,812
Total comprehensive income for the year	**-**	**16,812**	**16,812**
Dividends		(17,000)	(17,000)
Total investments by and distributions to owners	**-**	**(17,000)**	**(17,000)**
At 30 June 2022	**1,000**	**(901)**	**99**
At 01 July 2022	**1,000**	**(901)**	**99**
Profit for the year		(1,548)	(1,548)
Total comprehensive income for the year	**-**	**(1,548)**	**(1,548)**
Total investments by and distributions to owners	**-**	**-**	**-**
At 30 June 2023	**1,000**	**(2,449)**	**(1,449)**

ASSET PHARMA RESOURCES LIMITED
Notes to the Financial Statements
For the year ended 30 June 2023

General Information
ASSET PHARMA RESOURCES LIMITED is a private company, limited by shares, registered in England & Northern Ireland, registration number 06946223, registration address Kao Hockham Building, Edinburgh Way, Harlow, ESSEX, CM20 2NQ.

The presentation currency is £ sterling.

1. **Accounting policies**

Significant accounting policies

Statement of compliance

These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

Basis of preparation

The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.

The financial statements are prepared in sterling which is the functional currency of the company.

Turnover

Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.

Tangible fixed assets

Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Computer Equipment	33.33% Straight Line

2. **Average number of employees**

Average number of employees during the year was 1 (2022 : 1).

3. Tangible fixed assets

Cost or valuation	Computer Equipment	**Total**
	£	**£**
At 01 July 2022	1,773	1,773
Additions	-	-
Disposals	-	-
At 30 June 2023	**1,773**	**1,773**
Depreciation		
At 01 July 2022	1,773	1,773
Charge for year	-	-
On disposals	-	-
At 30 June 2023	**1,773**	**1,773**
Net book values		
Closing balance as at 30 June 2023	**-**	**-**
Opening balance as at 01 July 2022	**-**	**-**

4. Debtors: amounts falling due within one year

	2023	**2022**
	£	**£**
Other Debtors	18,719	0
Director: Christopher Bouffard	0	11,281
VAT	60	60
	18,779	**11,341**

5. Creditors: amount falling due within one year

	2023	2022
	£	£
Trade Creditors	73	73
Corporation Tax	830	4,773
	903	**4,846**

6. Creditors: amount falling due after more than one year

	2023	2022
	£	£
BBSL Loan	19,515	25,000
	19,515	**25,000**